Zoetis Inc. $ZTS Shares Sold by Fishman Jay A Ltd. MI

Key Points

• Fishman Jay A Ltd. MI decreased its ownership in Zoetis Inc. by 85.3%, leaving it with 1,496 shares valued at approximately $233,000.
• Despite the sell-off by some investors, several institutions including Lindbrook Capital LLC and Scott & Selber Inc. have increased their stakes in Zoetis, indicating strong institutional interest.
• Zoetis recently reported better-than-expected earnings, with an EPS of $1.76, and has set its FY 2025 guidance between $6.300 and $6.400 EPS.

Fishman Jay A Ltd. MI trimmed its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 85.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,496 shares of the company's stock after selling 8,670 shares during the period. Fishman Jay A Ltd. MI's holdings in Zoetis were worth $233,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Lindbrook Capital LLC boosted its holdings in shares of Zoetis by 1.8% in the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company's stock valued at $612,000 after acquiring an additional 65 shares in the last quarter. Scott & Selber Inc. boosted its holdings in shares of Zoetis by 0.6% in the second quarter. Scott & Selber Inc. now owns 11,652 shares of the company's stock valued at $1,817,000 after acquiring an additional 67 shares in the last quarter. Secure Asset Management LLC boosted its holdings in shares of Zoetis by 2.9% in the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company's stock valued at $382,000 after acquiring an additional 68 shares in the last quarter. Quotient Wealth Partners LLC boosted its holdings in shares of Zoetis by 2.3% in the first quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company's stock valued at $521,000 after acquiring an additional 72 shares in the last quarter. Finally, Broadway Wealth Solutions Inc. boosted its holdings in shares of Zoetis by 4.4% in the first quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company's stock valued at $287,000 after acquiring an additional 73 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Down 0.0%

Shares of NYSE:ZTS opened at $146.45 on Monday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The company has a market cap of $64.91 billion, a PE ratio of 25.21, a price-to-earnings-growth ratio of 2.35 and a beta of 0.90. Zoetis Inc. has a 52 week low of $139.34 and a 52 week high of $196.55. The firm has a 50 day simple moving average of $149.79 and a 200 day simple moving average of $155.02.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm's quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on ZTS shares. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their price objective for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and decreased their price objective for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Weiss Ratings reissued a "hold (c-)" rating on shares of Zoetis in a research note on Saturday, September 27th. Finally, Piper Sandler increased their target price on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Five equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, Zoetis currently has an average rating of "Moderate Buy" and a consensus price target of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.